These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
190 related items for PubMed ID: 25821316
1. Effects of combination of aliskiren and pentoxyfylline on renal function in the rat remnant kidney model of chronic renal failure. Soni HM, Patel PP, Patel S, Rath AC, Acharya A, Trivedi HD, Jain MR. Indian J Pharmacol; 2015; 47(1):80-5. PubMed ID: 25821316 [Abstract] [Full Text] [Related]
6. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Nephrol Dial Transplant; 2004 May; 19(5):1106-15. PubMed ID: 14993492 [Abstract] [Full Text] [Related]
7. Gene expression profiling in the remnant kidney model of wild type and kinin B1 and B2 receptor knockout mice. Schanstra JP, Bachvarova M, Neau E, Bascands JL, Bachvarov D. Kidney Int; 2007 Aug; 72(4):442-54. PubMed ID: 17579666 [Abstract] [Full Text] [Related]
9. Functional and molecular evaluation of using aliskiren during acute and chronic partial ureteral obstruction in rat solitary kidney. Essam M, Barakat N, Elkashef A, Awadalla A, Behery AE, Abdel-Maboud M. Life Sci; 2021 Jan 15; 265():118811. PubMed ID: 33259867 [Abstract] [Full Text] [Related]
10. The synergistic effect of mizoribine and a direct renin inhibitor, aliskiren, on unilateral ureteral obstruction induced renal fibrosis in rats. Sakuraya K, Endo A, Someya T, Hirano D, Murano Y, Fujinaga S, Ohtomo Y, Shimizu T. J Urol; 2014 Apr 15; 191(4):1139-46. PubMed ID: 24140549 [Abstract] [Full Text] [Related]
12. Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agents. Kavvadas P, Weis L, Abed AB, Feldman DL, Dussaule JC, Chatziantoniou C. Hypertension; 2013 Apr 15; 61(4):901-7. PubMed ID: 23438929 [Abstract] [Full Text] [Related]
13. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi S. J Renin Angiotensin Aldosterone Syst; 2012 Mar 15; 13(1):122-7. PubMed ID: 21946392 [Abstract] [Full Text] [Related]
15. Effects of chronic administration of somatostatin analogue SMS 201-995 on the progression of chronic renal failure in subtotal nephrectomized rats. Uemasu J, Tokumoto A, Godai K, Kawasaki H, Hirayama C. Exp Clin Endocrinol; 1990 Sep 15; 96(1):97-104. PubMed ID: 2279532 [Abstract] [Full Text] [Related]
16. Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study. Soji K, Doi S, Nakashima A, Sasaki K, Kawai T, Aoki A, Kyuden Y, Fujiwara K, Yokoyama Y, Masaki T. Clin Exp Nephrol; 2015 Aug 15; 19(4):631-8. PubMed ID: 26293451 [Abstract] [Full Text] [Related]
17. Renoprotective effects of the direct renin inhibitor aliskiren on gentamicin-induced nephrotoxicity in rats. Bae EH, Kim IJ, Joo SY, Kim EY, Choi JS, Kim CS, Ma SK, Lee J, Kim SW. J Renin Angiotensin Aldosterone Syst; 2014 Dec 15; 15(4):348-61. PubMed ID: 23420778 [Abstract] [Full Text] [Related]